Because weight is relevant to idiopathic intracranial hypertension, weight loss with GLP-1 drugs offers one reason to study these medicines. Researchers have also tested whether a drug can lower pressure directly.
What the pressure trial measured
A small trial randomized 15 women with active disease to exenatide or placebo [2]. The researchers measured pressure directly. It was lower with exenatide at 2.5 hours and 24 hours. The 12-week result met the trial's prespecified threshold of p<0.10, with p=0.058.
The study was too small to establish long-term benefit or explain how pressure changed. An uncertain result for body mass index cannot establish whether weight played a role.
What the pooled studies found
The 2025 review covered 1,550 patients across a trial, a nonrandomized study and two registry studies [1]. Different subsets contributed to different outcomes. The estimated relative risk for papilledema was 0.25 (95% CI 0.15 to 0.43). Papilledema means swelling of the optic disc.
The headache risk estimate was imprecise. It ranged from a substantial reduction to a slight increase. The studies reported digestive symptoms, with limited evidence to estimate uncommon or long-term harms.
Suspected intracranial hypertension needs clinical assessment. Treatment decisions depend on symptoms, pressure and the risk to vision.